行情

NVUS

NVUS

Novus
NASDAQ

实时行情|Nasdaq Last Sale

0.3601
+0.0071
+2.01%
已收盘, 16:00 04/08 EDT
开盘
0.3480
昨收
0.3530
最高
0.3612
最低
0.3201
成交量
4.39万
成交额
--
52周最高
4.410
52周最低
0.2500
市值
578.66万
市盈率(TTM)
-0.2558
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVUS价格均价为2.583,最高价位3.250,最低价为2.000。

EPS

NVUS 新闻

更多
  • 收盘:关注疫情发展 美股收高道指涨逾700点
  • 新浪美股 · 25分钟前
  • 机构:本季度股市还有一次逢低买入机会
  • 新浪财经-自媒体综合 · 38分钟前
  • 周三黄金期货微涨60美分 白银期货收跌1.8%
  • 新浪美股 · 46分钟前
  • 债务迅速增长 全球经济或遭“重挫”
  • 新浪财经-自媒体综合 · 46分钟前

所属板块

制药
+3.07%
制药与医学研究
+3.10%

热门股票

代码
价格
涨跌幅

NVUS 简况

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
展开

微牛提供Novus Therapeutics Inc(NASDAQ-NVUS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVUS股票新闻,以帮助您做出投资决策。